Today at the 2011 Bio International Convention, we had the opportunity to speak with Keith A. Katkin, President and Chief Executive Officer of Avanir Pharmaceuticals. Katkin discusses the recent FDA approval of Nuedexta for the treatment of pseudobulbar affect (PBA).

[youtube]http://www.youtube.com/watch?v=GApXXbmHWHs[/youtube]